New dermatitis drug candidate begins first human safety tests
NCT ID NCT07414602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a single dose of the experimental drug SHR-1894 is safe and how it moves through the body. It involves 40 healthy adults aged 18 to 45. No treatment is given; the goal is to gather safety information before testing in patients with dermatitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spray vs. ointment: which works better for incontinence rash?
- New eczema drug shows promise in Mid-Stage trial
- AI boosts skin diagnosis accuracy in small trial
- Light therapy eases mouth sores and skin burns in 33,000 cancer patients
- Ear spray showdown: can ectoin soothe outer ear itch?
- New pill for Kids' eczema itch shows promise in large trial